Investors turned a bit skittish on medical stocks Monday, as Gilead Sciences (GILD) plunged after Express Scripts (ESRX) announced it would support the hepatitis C drug from AbbVie (ABBV), rather than Gilead’s Sovaldi. But two IBD Stock Spotlight pharmaceuticals, Actavis (ACT) and Valeant Pharmaceuticals (VRX), took comparatively mild hits. Ireland-based Actavis eased in weak trade.